Diagnosis of preeclampsia with soluble Fms-like tyrosine kinase 1/placental growth factor ratio: an inter-assay comparison

Tools

Item Type:	Article
Title:	Diagnosis of preeclampsia with soluble Fms-like tyrosine kinase 1/placental growth factor ratio: an inter-assay comparison
Creators Name:	Andersen, L.B., Frederiksen-Møller, B., Work Havelund, K., Dechend, R., Jørgensen, J.S., Jensen, B.L., Nielsen, J., Lykkedegn, S., Barington, T. and Christesen, H.T.
Abstract:	The angiogenic factor ratio soluble Fms-kinase 1 (sFlt-1)/placental growth factor (PlGF) is a novel diagnostic tool for preeclampsia. We compared the efficacy of the KRYPTOR (BRAHMS) automated assays for sFlt-1 and PlGF with the Elecsys (Roche) assays in a routine clinical setting. Preeclamptic women (n = 39) were included shortly after the time of diagnosis. Normotensive control pregnancies were matched by gestational age (n = 76). The KRYPTOR assays performed comparably or superior to Elecsys (sFlt-1/PlGF area under the curve 0.746 versus 0.735; P = .09; for non-obese 0.820 versus 0.805, P = .047). For early-onset preeclampsia, KRYPTOR area under the curve increased to 0.929 with a 100% specificity for preeclampsia at cut-off 85 and an 88.9% sensitivity for preeclampsia at cut-off 33. For women with preeclampsia and preterm delivery or Hemolysis, Elevated Liver enzymes, Low Platelet count (HELLP) syndrome, the KRYPTOR sFlt-1/PlGF ratio was manifold increased (P < .01). The sFlt-1/PlGF ratio proved especially useful in early-onset preeclampsia, preeclampsia with preterm delivery or HELLP, and among non-obese women.
Keywords:	Hypertension, Obesity, Pregnancy, HELLP Syndrome
Source:	Journal of the American Society of Hypertension
ISSN:	1933-1711
Publisher:	Elsevier
Volume:	9
Number:	2
Page Range:	86-96
Date:	February 2015
Official Publication:	https://doi.org/10.1016/j.jash.2014.11.008
PubMed:	View item in PubMed

Repository Staff Only: item control page